FDA says Soulaire marketed an ECP device for unapproved uses without clearance or approval.
What happened
FDA reviewed Soulaire's website, https://www.soulaire.com/, on December 7, 2023. FDA found the External Counterpulsation System Model: Soulaire promoted for many uses outside its August 28, 2020 clearance (K202108), such as growing new arteries, reducing or eliminating blood pressure medicine, helping COVID-19 symptoms, excreting stem cells, regenerating pancreatic tissue, and hair growth. FDA also found the site offered the device for sale to "business, . . . home or sports team" even though its cleared labeling requires healthcare professional oversight and is Rx Only.
What FDA found
FDA says the company marketed the Soulaire ECP device in the U.S. without FDA approval to market or approval for study use for the described uses.
section 501(f)(1)(B), 21 U.S.C. § 351(f)(1)(B); sections 515(a) and 520(g), 21 U.S.C. §§ 360e(a), 360j(g)FDA says the company promoted the device for uses beyond its cleared indications, including growing new arteries, reducing blood pressure medicine, COVID-19 symptoms, stem cell repair, pancreatic regeneration, and hair growth, without a new premarket notification to FDA.
section 502(o), 21 U.S.C. § 352(o); 21 CFR 807.81(a)(3)(ii)FDA says the company did not notify FDA of its intent to commercially distribute the device as required by 510(k).
section 502(o), 21 U.S.C. § 352(o); section 510(k), 21 U.S.C. § 360(k)FDA says the website offered the device for sale to business, home, or sports team, although the cleared labeling requires healthcare professional oversight and says Rx Only.
FDA says the website made unsubstantiated claims that make the device intended to treat diabetes, heart failure, stroke, COVID-19, and other conditions, and to affect body structures or functions.
section 201(h), 21 U.S.C. § 321(h)
What FDA wants
FDA asks Soulaire to stop activities that misbrand or adulterate the device, including commercial distribution for uncleared uses, and to respond in writing within 15 business days with the steps taken, corrective actions, and a plan to prevent recurrence.
Who should pay attention
- patients considering external counterpulsation therapy
- clinics and physicians asked to order or oversee ECP devices
- distributors or retailers selling medical devices with unapproved claims
This is a summary. Read the original letter on fda.gov.